The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...
GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has entered into a research ...
Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, today announced the successful identification of functional antibody clusters targeting ...
Candidate selection underscores Confo’s ability to rapidly advance differentiated GPCR-targeting therapeutics and its focus on metabolic and endocrine disorders Cedric Ververken, CEO of Confo ...
AbbVie is paying $255 million cash to acquire British biotech DJS Antibodies and its platform for targeting transmembrane proteins. DJS is focused on difficult-to-drug disease-causing proteins, such ...
Adhesion G protein-coupled receptors have a large extracellular region (shown in green and orange) that extends into space outside the cell. Almost 35% of drugs approved by the Food and Drug ...
Most protein-targeting drugs are prizes that drug developers have unearthed from G protein–coupled receptor (GPCR) interactomes. So, when GPCR-targeting drugs become harder to find, one might liken ...
This new technique for studying cell receptors could have sweeping implications for drug development
One in every three FDA-approved drugs targets a single superfamily of receptors dotting the surfaces of human cells. From beta blockers to antihistamines, these essential, life-saving medications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback